Treatment outcomes of persistent pulmonary Hypertension of the Newborn in Neonates with Gestational Ages >34 weeks at Maharat Nakhon Ratchasima Hospital
Article Sidebar
Main Article Content
Abstract
Persistent pulmonary hypertension of the newborn (PPHN) contributes to neonatal hypoxia and it is associated with high morbidity and mortality. Objective: To determine the mortality rate and treatment outcomes of the neonates with PPHN. Patients & Method: A retrospective descriptive study was performed by reviewing the medical records of neonates with PPHN admitted at Maharat Nakhon Ratchasima Hospital between January 2007 and December 2009. Results: Eighty-four neonates with PPHN were enrolled. The causes of PPHN were meconium aspiration syndrome (41.7%), birth asphyxia (19.0%), congenital pneumonia (16.7%), respiratory distress syndrome (11.9%) and congenital diaphragmatic hernia (7.1%). The mortality rate of neonates with PPHN was 46.4%. Birth asphyxia, late preterm infants (GA 34-37 weeks), more fluid intake, higher mean airway pressure, more administration of sodium bicarbonate and pneumothorax correlated with high mortality rate, Chronic lung diseases, delayed developments and hearing loss in 1-year follow up were found. Conclusion: PPHN was the important problem in neonate that associated with high morbidity and mortality rate especially with birth asphyxia, late preterm infant and pneumothorax. Optimized lung expansion strategy and effective pulmonary vasodilators should be used in patients to improve survival rates.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Konduri GG, Kim UO. Advances in the diagnosis and management of persistent pulmonary hypertension of the newborn. Pediatr Clin North Am 2009; 56: 579-600.
UK collaborative randomised trial of neonatal extracorporeal membrane oxygenation. UK Collaborative ECMO Trail Group. Lancet 1996; 348: 75-82.
Bruckheimer E, Eidelman Al. Persistent pulmonary hypertension and ECMO. Pediatrics 1990; 86: 809-11.
Elbourne D, Field D, Mugford M. Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants. Cochrane Database Syst Rev 2002: CD 001340.
Chotigeat U, Khorana M, Kanjanapatakul W. Outcome of neonates with persistent pulmonary hypertension of the newborn treated with inhaled nitric oxide. J Med Assoc Thai 2002; 85: 800-7.
Chotigeat U, Khorana M, Kanjananattanakul W. Inhaled nitric oxide in newborns with severe hypoxic respiratory failure. J Med Assoc Thai 2007; 90: 266-71.
Kinsella JP, Truog WE, Walsh WF, Goldberg RN, Bancalari E, Mayock DE, et al Randomized, multicenter trial of inhaled nitric oxide and high-frequency oscillatory ventilation in severe, persistent pulmonary hypertension of the newborn. J Pediatr 1997; 131: 55-62.
Roberts JD, Jr., Fineman JR, Morin FC, 3rd, Shaul PW, Rimar S, Schreiber MD, et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newbom. The Inhaled Nitric Oxide Study Group. N Engl J Med 1997; 336: 605-10.
Chotigcat U, Jaratwashirakul S. Inhaled iloprost for severc persistent pulmonary hypertension of the newbom. J Med Assoc Thai 2007; 90: 167-70.
Kelly LK, Porta NF, Goodman DM, Carroll CL, Steinhorn RH. Inhaled prostacyclin for term infants with persistent pulmonary hypertension refractory to inhaled niric oxide. J Pediatr 2002; 141: 830-2.
Golzand E, Bar-Oz B, Arad I. Intravenous prostacyclin in the treatment of persistent pulmonary hypertension of the newbom refractory to inhaled nitric oxide. Isr Med Assoc J 2005; 7:408-9.
Baquero H, Soliz A, Neira F, Venegas ME, Sola A. Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: a pilot randomized blinded study. Pediatrics 2006; 117: 1077-83.
Bassler D, Kreutzer K, McNamara P, Kirpalani H. Milrinone for persistent pulmonary hypertension of the newborn. Cochrane Database Syst Rev: CD007802.
McNamara PJ, Laique F, Muang-In S, Whyte HE.
Milrinone improves oxygenation in neonates with severe persistent pulmonary hypertension of the newbom. J Crit Care 2006; 21: 217-22.
Ho JJ, Rasa G. Magnesium sulfate for persistent pulmonary hypertension of the newborn. Cochrane Database Syst Rev 2007: CD005588.
Krishnan L, Souza NA, Baliga M. Treatment of severe
persistent pulmonary hypertension of newbom with magnesium sulfate. Indian J Pediatr 1993; 60: 597-600.
Lipkin PH, Davidson D, Spivak L, Straube Rhines J, Chang CT. Neurodevelopmental and medical outcomes of persistent pulmonary hypertension in term newborns treated with nitric oxide. J Pediatr 2002; 140: 306-10.
Hosono S, Ohno T, Kimoto H, Shimizu M, Takahashi S, Harada K. Developmental outcomes in persistent pulmonary hypertension treated with nitric oxide therapy. Pediatr Int 2009; 51: 79-83.
Rosenberg AA, Lee NR, Vaver KN, Werner D, Fashaw L, Hale K, et al. School-age outcomes of newborns treated for persistent pulmonary hypertension. J Perinatol 30: 127-34
Walsh-Sukys MC, Tyson JE, Wright LL, Bauer CR, Korones SB, Stevenson DK, et al. Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. Pediatrics 2000; 105: 14-20.
Konduri GG, Solimano A, Sokol GM, Singer J, Ehren- kranz RA, Singhal N, etal. A randomized trial of early versus standard inhaled nitric oxide therapy in term and near-term newbom infants with hypoxic respiratory failure. Pediatrics 2004; 113: 559-64.
Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C,Mitchell AA. Risk factors for persistent pulmonary hypertension of the newbom. Pediatrics 2007; 120:e272- 82.
Hwang SJ, Lee KH, Hwang JH,Choi CW,Shim JW, Chang YS, et al. Factors affecting the response inhaled nitric oxide therapy in persistent pulmonary hypertension of the newborn infants. Yonsei Med J 2004; 45: 49-55.
Lotze A, Mitchell BR, Bulas DI, Zola EM, Shalwitz RA, Gunkel JH. Multicenter study of surfactant (beractant) use in the treatment of term infants with severe respiratory failure. Survanta in Term Infants Study Group. J Pediatr 1998; 132: 40-7.
Marron MJ, Crisafi MA, Driscoll Jr, Wung JT, Driscoll YT, Fay TH, et al. Hearing and neurodevelopmental outcome in survivors of persistent pulmonary hypertension of the newborn. Pediatrics 1992; 90:392-6.